Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
27,739,221
-
Share change
-
+1,930,129
-
Total reported value
-
$194,003,698
-
Put/Call ratio
-
159%
-
Price per share
-
$7.00
-
Number of holders
-
99
-
Value change
-
+$12,734,175
-
Number of buys
-
38
-
Number of sells
-
52
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q4 2020
As of 31 Dec 2020,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
99 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
27,739,221 shares.
The largest 10 holders included
TRV GP II, LLC, TRV GP III, LLC, CITADEL ADVISORS LLC, BlackRock Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., DIMENSIONAL FUND ADVISORS LP, Woodline Partners LP, Sofinnova Investments, Inc., VANGUARD GROUP INC, and Erste Asset Management GmbH.
This page lists
99
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.